Next-Generation HIF-2α Inhibitor Shows Promise in Kidney Cancer Translational Clinical Trial (IMAGE)

Dana-Farber Cancer Institute

Next-Generation HIF-2α Inhibitor Shows Promise in Kidney Cancer Translational Clinical Trial

Caption

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, led the single-arm ARC-20 clinical trial which evaluated casdatifan, a next-generation HIF-2α inhibitor, as monotherapy for metastatic clear cell renal cell carcinoma.

Credit

Dana-Farber Cancer Institute

Usage Restrictions

Kindly courtesy Dana-Farber Cancer Institute

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.